Thus, it is possible that APRIL expressed by AECs in the lungs of patients with COPD and NSCLC contributes to the progression of each disease by activating B cells and macrophages in the lungs (and/or tumor cells in the case of patients with NSCLC). This evidence concerns the gene TNFSF13 and non-small cell lung carcinoma.